## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A benzimidazole acetonitrile according to formula (I)

$$R^1$$
 $N$ 
 $CN$ 
 $G$ -L

as well as its tautomers, its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

G is a pyrimidinyl;

L is an amino group, or a 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from N, O, S or L is an acylamino moiety;

R<sup>1</sup> is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, carboxy, amino carbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl or C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryl, halogen, cyano or hydroxy;

 $R^2$  is selected from the group comprising or consisting of hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, or  $C_1$ - $C_6$ -alkoxy.

Claim 2 (Original): The benzimidazole acetonitrile according to claim 1, wherein  $R^1$  is H or  $C_1$ - $C_3$  alkyl.

Claim 3 (Currently Amended): The benzimidazole acetonitrile according to any of elaims 1 or 2 Claim 1, wherein  $R^2$  is a  $C_1$ - $C_3$  alkyl.

Claim 4 (Currently Amended): The benzimidazole acetonitrile according to any of claims 1 to 3 Claim 1, having any of the formulae

wherein R<sup>1</sup> is as above defined, and

 $R^3$  is selected from the group comprising or consisting of hydrogen,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, or  $C_1$ - $C_6$ -alkoxy;

L is an amino group of the formula -NR $^5$ R $^6$  wherein R $^5$  and R $^6$  are each independently from each other H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkenyl aryl, , C<sub>1</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl, or

R<sup>5</sup> and R<sup>6</sup> may form a ring together with the nitrogen to which they are bound.

Claim 5 (Currently Amended): The benzimidazole acetonitrile according to any of the preceding claims Claim 1, wherein R<sup>5</sup> is hydrogen or a methyl or ethyl or propyl group and R<sup>6</sup> is a selected from the group consisting of H, (C<sub>1</sub>-C<sub>10</sub>)-alkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl-heteroaryl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl and 4-8 membered saturated or unsaturated cycloalkyl.

Claim 6 (Currently Amended): The benzimidazole acetonitrile according to any of the preceding claims Claim 1, wherein R<sup>5</sup> is H and R<sup>6</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl.

Claim 7 (Currently Amended): The benzoxazole acetonitrile according to any-of elaims 1 to 3 Claim 1, wherein L is an acylamino moiety of the formula -NR<sup>5</sup>C(O)R<sup>6</sup> wherein R<sup>5</sup> and R<sup>6</sup> are each independently from each other H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl.

Claim 8 (Currently Amended): The benzimidazole acetonitrile according to any of the preceding claims Claim 1 selected from the group consisting of:

(2Z)-(l-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(1H-pyrazol-l-yl)propyl]amino}pyrimidin-4-yl)acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(1H-pyrazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile

(2Z)-[2-(cyclobutylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile

- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(1H-1,2,4-triazol-l-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(5-methyl-2-{[3-(1H-1,2,4-triazol-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- [2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile
- (2Z)-(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)(1-propyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
- (1-ethyl-lH-benzimidazol-2-yl){5-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
- (2Z)-[2-(cyclobutylamino)pyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
- (2Z)-[2-(cycloheptylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile
- [2-(cyclopentylamino)pyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile 1,3-dihydro-2H-benzimidazol-2-ylidene(5-methyl-2-{[3-(2-oxopyrrolidin-l-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- (2Z)-(1-cyclobutyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}pyrimidin-4-yl)acetonitrile
- (1-ethyl-1H-benzimidazol-2-yl){2-[(2-pyridin-3-yl-ethyl)amino]pyrimidin-4-yl}acetonitrile
- (2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[2-(isobutylamino)-5-methylpyrimidin-4-yl]acetonitrile

(2Z)-(l-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-4-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[2-(isobutylamino)pyrimidin-4-yl]acetonitrile

[2-(cyclopropylamino)pyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile [2-({2-[6-(dimethylamino)pyridin-3-yl]ethyl}amino)pyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile

(1-ethyl-1H-benzimidazol-2-yl)(2-{[2-(1H-1,2,4-triazol-1-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile

[2-({2-[6-(dimethylamino)pyridin-3-yl]ethyl}amino)-5-methylpyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile

(2Z)-[2-(cycloheptylamino)pyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

[2-(cyclopropylamino)-5-methylpyrimidin-4-yl](1-ethyl-1H-benzimidazol-2-yl)acetonitrile

(1-ethyl-1H-benzimidazol-2-yl){2-[(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl}acetonitrile

[2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

[2-(cyclohexylamino)pyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile (2Z)-(l-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(lH-indol-3-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile

```
Preliminary Amendment
Docket No. 285216USOPCT

(1-ethyl-IH-benzimidazol-2-yl){5-methyl-2-[(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl}acetonitrile

{2-[(2-ethoxyethyl)amino]pyrimidin-4-yl}(1-ethyl-1H-benzimidazol-2-yl)acetonitrile
(1-ethyl-1H-benzimidazol-2-yl){5-methyl-2-[(1-methylbutyl)amino]pyrimidin-4-yl}acetonitrile
(1-ethyl-1H-benzimidazol-2-yl)[2-(methylamino)pyrimidin-4-yl]acetonitrile
(1-ethyl-1H-benzimidazol-2-yl)(5-methyl-2-{[2-(1H-pyrazol-1-yl)ethyl]amino}pyrimidin-4-yl)acetonitrile
1H-benzimidazol-2-yl{5-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)(2-{[2-(1H-imidazol-1-yl)ethyl]amino}-5-methylpyrimidin-4-yl)acetonitrile
```

1H-benzimidazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile
(1-ethyl-lH-benzimidazol-2-yl){2-[(1-methylbutyl)amino]pyrimidin-4-yl}acetonitrile
{2-[(cyclohexylmethyl)amino]-5-methylpyrimidin-4-yl}(1-ethyl-lH-benzimidazol-2-yl)acetonitrile

1H-benzimidazol-2-yl[2-(cyclopentylamino)pyrimidin-4-yl]acetonitrile
(1-ethyl-1H-benzimidazol-2-yl){6-methyl-2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}acetonitrile

1H-benzimidazol-2-yl[2-(cyclopropylamino)pyrimidin-4-yl]acetonitrile
[2-(cyclopentylamino)-6-methylpyrimidin-4-yl](1-ethyl-lH-benzimidazol-2-yl)acetonitrile

{2-[(cyclohexylmethyl)amino]pyrimidin-4-yl}(1-ethyl-lH-benzimidazol-2-yl)acetonitrile

(1-ethyl-1H-benzimidazol-2-yl) {6-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl} acetonitrile

(1-ethyl-lH-benzimidazol-2-yl){2-[(3-pyrrolidin-l-ylpropyl)amino]pyrimidin-4-yl}acetonitrile

(1-ethyl-lH-benzimidazol-2-yl)[2-(4-ethylpiperazin-l-yl)-5-methylpyrimidin-4-yl]acetonitrile

(1-ethyl-1H-benzimidazol-2-yl){2-[(2-furylmethyl)amino]-5-methylpyrimidin-4-yl}acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) {5-methyl-2-[(1-methylpiperidin-4-yl)amino]pyrimidin-4-yl} acetonitrile

(2Z)-[2-(cyclohexylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

(2Z)-[2-(ethylamino)-5-methylpyrimidin-4-yl](1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

[2-(cyclopentylamino)-5-methylpyrimidin-4-yl](1,3-diethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)[5-methyl-2-(piperidin-4-ylamino)pyrimidin-4-yl]acetonitrile

(2Z)-(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) {5-methyl-2-[(2-piperidin-l-ylethyl)amino]pyrimidin-4-yl} acetonitrile

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-(4-methylpiperazin-1-yl)-4-oxobutanamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]pyrimidin-2-yl}-4-(4-methylpiperazin-l-yl)-4-oxobutanamide

(1R,5R,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

 $(1S,5S,7S)-N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-yl]-6,8-dioxa-3-azabicyclo[3.2.1] octane-7-carboxamide$ 

(1S,4S,5S,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methyl-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

(1S,4R,5S,7R)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methyl-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperazine-2-carboxamide

(4S)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1,3-thiazolidine-4-carboxamide

 $(4R)-N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\}-1,3-thiazolidine-4-carboxamide$ 

N-{4-[(Z)-cyano(1-ethyl-l,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl)-5-oxo-L-prolinamide

4-tert butyl 1-(9H-fluoren-9-ylmethyl)2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]piperazine-1,4-dicarboxylate

tert-butyl (4S)-4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-1,3-thiazolidine-3-carboxylate

tert-butyl (2S)-2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-5-oxopyrrolidine-l-carboxylate

tert-butyl (4R)-4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]-1,3-thiazolidine-3-carboxylate

2-(1-acetylpiperidin-4-yl)-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}acetamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-methylmorpholine-2-carboxamide

4-acetyl-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}morpholine-2-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide

tert-butyl 3-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]piperidine-l-carboxylate

tert butyl 4-[2-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-

 $ylidene) methyl] -5 - methylpyrimidin -2 - yl\} amino) -2 - oxoethyl] piperidine -1 - carboxylate$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}morpholine-2-carboxamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-piperidin-4-ylacetamide

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperidine-3-carboxamide

tert-butyl 2-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]morpholine-4-carboxylate

N-[3-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-3-oxopropyl]benzamide

tert-butyl [2-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-2-oxoethyl]methylcarbamate

 $N-(4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\}-1-methylpiperidine-3-carboxamide$ 

 $N\sim 1\sim -\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\}-N\sim 2\sim -methylglycinamide$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}pyrrolidine-3-carboxamide

tert-butyl 3-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]pyrrolidine-l-carboxylate

(2S)-N-(4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide

 $tert-butyl\ (2S)-2-[(\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-yl]-5-methylpyrimidin-2-yl] amino) carbonyl]-2,5-dihydro-1H-pyrrole-1-carboxylate$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-(2-methoxyphenyl)acetamide

 $1-acetyl-N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\} piperidine-4-carboxamide$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-1-methylpiperidine-4-carboxamide

4-amino-N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}butanamide

tert-butyl 4-[({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)carbonyl]piperidine-1-carboxylate

N-{4-[(Z)-cyano(1-ethyl-l,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}piperidine-4-carboxamide

tert-butyl [4-({4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}amino)-4-oxobutyl]carbamate

 $N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\} cyclopentanecarboxamide$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl)-4-(4-methylpiperazin-l-yl)butanamide

 $N\sim1\sim-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\}-N\sim3\sim,N\sim3\sim-dimethyl-beta-alaninamide$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-4-(dimethylamino)butanamide

(2Z)-(2-amino-5-methylpyrimidin-4-yl)(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)acetonitrile

 $N-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-yliene) methyl]-5-methylpyrimidin-2-yl\}-2-morpholin-4-ylacetamide$ 

 $N\sim2\sim-benzyl-N\sim1\sim-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene) methyl]-5-methylpyrimidin-2-yl\} glycinamide$ 

N-{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl}-2-(1,1-dioxidothiomorpholin-4-yl)acetamide

 $N\sim1\sim-\{4-[(Z)-cyano(1-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)methyl]-5-methylpyrimidin-2-yl\}-N\sim2\sim-formylglycinamide.$ 

Claim 9 (Currently Amended): A benzimidazole acetonitrile according to any of the preceding claims Claim 1 for use as a the preparation of a medicament.

Claim 10 (Currently Amended): Use of a A benzimidazole acetonitrile according to any of claims 1 to 8 Claim 1 in the preparation of a medicament for the prevention and/or treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS).

Claim 11 (Currently Amended): Use of an The benzimidazole acetonitrile according to claim 9 wherein the disease is diabetes type II.

Claim 12 (Currently Amended): A pharmaceutical composition containing a benzimidazole acetonitrile according to any of the claims 1 to 8 Claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 13 (Currently Amended): [[A]] The composition according to claim 12, further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides, thiazolidines, PPARs agonists, GSK-3 inhibitors.

Claim 14 (Currently Amended): Composition The composition according to claim 13 wherein said supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat,

Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8, AD-5467, ZD5522, M-16209, NZ-314, M-79175, SPR-210, ADN 138, or SNK-860, Miglitol, Acarbose, Glipizide, Glyburide, Chlorpropamide, Tolbutamide, Tolazamide, or Glimepriride.

Claim 15 (Currently Amended): A method of preparing a benzimidazole acetonitrile of formula (I) according to any of the claims 1 to 8 Claim 1, comprising the following step:

wherein R<sup>1</sup>, R<sup>2</sup>,G, L are as above described.

Claim 16 (Currently Amended): A method of preparing a benzimidazole acetonitrile of formula (I) according to any of the claims 1 to 8 Claim 1, comprising the following step:

$$\mathbb{R}^{2} \xrightarrow{\mathbb{R}^{2}} \mathbb{C} \mathbb{N} \longrightarrow \mathbb{R}^{2} \xrightarrow{\mathbb{R}^{2}} \mathbb{C} \mathbb{N} \longrightarrow \mathbb{R}^{2} \longrightarrow \mathbb{R}^{2}$$

Claim 17 (Currently Amended): A method according to claim 15 or 16, comprising the following steps:

$$R^{1} = \begin{pmatrix} N & CI & N & CI &$$

wherein  $R^1$ ,  $R^3$  and  $R^4$  are as above defined.

Second Claim 17 (Canceled).

Claim 18 (Canceled).

Claim 19 (New): The method according to claim 15, comprising the following steps:

wherein  $R^1$ ,  $R^3$  and  $R^4$  are as above defined.

Preliminary Amendment Docket No. 285216US0PCT

Claim 20 (New): The method according to claim 19, wherein the intermediate compound of formula (II) is selected from the group consisting of:

1,3-benzimidazol-2(3H)-ylidene(2-chloro-6-methylpyrimidin-4-yl)acetonitrile

1,3-benzimidazol-2(3H)-ylidene(2-chloro-6-methylpyrimidin-4-yl)acetonitrile

1,3-benzimidazol-2(3H)-ylidene(6-chloropyrimidin-4-yl)acetonitrile.